Brief: Prothena Announces Novo Nordisk Obtains Fast Track Designation From The U.S. FDA For Coramitug

Prothena

27/04/2026 21:07

April 27 (Reuters) - Prothena Corporation PLC PRTA.O:

PROTHENA ANNOUNCES NOVO NORDISK OBTAINS FAST TRACK DESIGNATION FROM THE U.S. FDA FOR CORAMITUG (PRX004) IN ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY

PROTHENA CORPORATION PLC - CORAMITUG PHASE 3 CLEOPATTRA TRIAL ENROLLS ~1,280 PARTICIPANTS; PRIMARY COMPLETION EXPECTED IN 2029

Source text: ID:nBw1cbWfVa

Further company coverage: PRTA.O

 ((Reuters.Briefs@thomsonreuters.com;))